{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000608","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2023-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.708824+00:00","generated_at":"2026-06-16T18:00:10.366670+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"USANA Q1 net sales $248M, EPS $0.95; raises FY23 guidance low end","bullets":["Net sales $248M, +9% sequentially but -9% YoY; diluted EPS $0.95 (+44% sequentially, -17% YoY).","FY2023 guidance raised: net sales $875-$950M (previously $850-$950M), EPS $2.40-$3.30 (prev $2.35-$3.30).","Active customers 491,000, flat sequentially, -11% YoY; Asia Pacific net sales $200M (80% of total).","Q1 included ~$12M China COVID-demand benefit and ~$13M price-increase pull-forward; new market expansion planned.","Ended quarter with $295M cash, debt-free; no share repurchases; $83M remaining under authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000608","json":"https://secwatch.observer/filing/0001157523-23-000608.json","markdown":"https://secwatch.observer/filing/0001157523-23-000608.md","text":"https://secwatch.observer/filing/0001157523-23-000608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000608/0001157523-23-000608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000608/a53387511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T18:00:10.366670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df06e3bec3778b30ecfd513162e5c2c91543a180","claim":"USANA HEALTH SCIENCES INC reported the first quarter ended April 1, 2023 results: revenue $248 million, EPS $0.95. Guidance raised.","evidence_excerpt":"First quarter net sales were $248 million versus $228 million for the fourth quarter of 2022 and $273 million during the first quarter of 2022. First quarter diluted EPS was $0.95 as compared with $0.66 for the fourth quarter of 2022 and $1.15 during the first quarter of 2022. Generated $13 million of operating cash flow during the quarter. Fiscal 2023 net sales and diluted EPS guidance updated to $875 to $950 million and $2.40 to $3.30, respectively, from $850 million to $950 million and $2.35 to $3.30.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000608/0001157523-23-000608-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended April 1, 2023"},{"label":"Revenue","value":"$248 million"},{"label":"EPS","value":"$0.95"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}